Description | Olinvacimab (TTAC-0001), a fully human anti-VEGFR2 monoclonal antibody, demonstrates antiangiogenic activity by inhibiting VEGF binding to KDR, with a dissociation constant (K d) of 0.23 nM. It is utilized in research for treating recurrent glioblastoma and breast cancer [1]. |
molecular weight | N/A |
CAS | 2095504-49-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |